Diabetes-specific Formula (DSF) in Individuals With Type 2 Diabetes

Sponsor
Abbott Nutrition (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05802927
Collaborator
(none)
66
2
3
4
33
8.2

Study Details

Study Description

Brief Summary

A randomized, controlled, crossover design with three treatments to determine the effects of diabetes-specific formula on glycemic control in individuals with type 2 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Other: DSF
  • Other: Breakfast 1
  • Other: Breakfast 2
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Trial to Determine the Effects of Diabetes-specific Formula on Glycemic Control in Individuals With Type 2 Diabetes
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Experimental: Diabetes-specific formula

Other: DSF
Diabetes-specific formula

Other: Experimental: Breakfast 1 Noodle Soup

Other: Breakfast 1
Noodle Soup

Other: Experimental: Breakfast 2 Glutinous rice

Other: Breakfast 2
Glutinous rice

Outcome Measures

Primary Outcome Measures

  1. Postprandial blood glucose [3 hours]

    Positive area under the curve (AUC) for blood glucose concentration from 0 to 180 minutes.

Secondary Outcome Measures

  1. Postprandial insulin [3 hours]

    Positive area under the curve (AUC) for blood insulin concentration from 0 to 180 minutes.

  2. Appetite [3 hours]

    Negative/Positive area under the curve (AUC) for each item of Appetite questionnaire from 0 to 180 minutes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Has type 2 diabetes as evidenced by use of oral antihyperglycemic medication(s).

  2. BMI > 18.5 and ≤ 35.0 kg/m2.

  3. Weight stable.

  4. Male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.

  5. If on chronic medication, the dosage to be constant for at least two months prior to screening visit and to maintain the medication and dose throughout the study.

  6. Willing to follow the protocol throughout the study.

  7. At least a two-week washout period between completion of a previous research study and their start in the current study.

  8. Willing to refrain from taking non-study diabetes-specific formulas over the course of the study.

  9. Voluntarily signed and dated an Informed Consent Form (ICF) prior to any participation in the study.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:
  1. Has a screening HbA1c level < 7% or ≥ 10%.

  2. Uses exogenous insulin for glucose control.

  3. Has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis.

  4. Has current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks.

  5. Has active malignancy.

  6. Has significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure.

  7. Has end stage organ failure or was post organ transplant.

  8. Has a history of renal disease or severe gastroparesis.

  9. Has current hepatic disease.

  10. Has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product.

  11. Has a chronic, contagious, infectious disease.

  12. Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.

  13. Taking any herbals, dietary supplements or medications other than allowed anti-hyperglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose or appetite.

  14. Uses diabetes-specific formula(s) defined as more than one eating occasion per week in the last three months.

  15. Has clotting or bleeding disorders.

  16. Participates in another study that has not been approved as a concomitant study by Abbott Nutrition.

  17. Has allergy or intolerance to any ingredient in the study product.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chulalongkorn University Bangkok Thailand 10330
2 Siriraj Hospital Bangkok Thailand 10700

Sponsors and Collaborators

  • Abbott Nutrition

Investigators

  • Study Chair: Agnes Siew Ling Tey, PhD, Abbott Nutrition R&D

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Abbott Nutrition
ClinicalTrials.gov Identifier:
NCT05802927
Other Study ID Numbers:
  • BL65
First Posted:
Apr 7, 2023
Last Update Posted:
Apr 7, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2023